Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
Results of PXL065 Phase 2 (DESTINY-1) trial in NASH expected in Q3 2022 LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that the U.S. Patent and Trademark Office (PTO) has … [Read more…]
